Yajie Hao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yajie Hao has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Limei Zhao
Department of Nephrology, The Fifth Clinical Medical College of Shanxi Medical University (Shanxi Provincial People’s Hospital), Taiyuan 030012, China
1 shared publication - Rongrong Wang
Department of Nephrology, The Fifth Clinical Medical College of Shanxi Medical University (Shanxi Provincial People’s Hospital), Taiyuan 030012, China
1 shared publication - Xiaoshuang Zhou
Department of Nephrology, The Affiliated People’s Hospital of Shanxi Medical University, Taiyuan, China
1 shared publication - Xiaoshuang Zhou
The Department of Nephrology, Shanxi Provincial People’s Hospital, Shanxi Medical University
1 shared publication - Xiu Huang
Department of Nephrology, The Fifth Clinical Medical College of Shanxi Medical University (Shanxi Provincial People’s Hospital), Taiyuan 030012, China
1 shared publication - Xiya Ren
Department of Nephrology, The Fifth Clinical Medical College of Shanxi Medical University (Shanxi Provincial People’s Hospital), Taiyuan 030012, China
1 shared publication
Latest Publications
- Open Access
- 9 September 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (18) , 2921
Non-Pharmacological Interventions for Sleep Quality and Related Symptoms in Patients with End-Stage Renal Disease: A Systematic Review and Meta-Analysis
Background: Sleep-related problems are common among patients receiving dialysis for end-stage renal disease (ESRD), while pharmacological management may be complicated by comorbidities, polypharmacy, and altered drug clearance. This systematic review and meta-analysis evaluated the effects of non-pharmacological interventions on sleep-related outcomes, anxiety symptoms, depressive symptoms, and fatigue symptoms in this population. Methods: PubMed, Embase, the Cochrane Library, and Web of Science were searched from inception to February 2026. The prespecified eligibility criterion was restricted to randomized controlled trials (RCTs) involving adults with ESRD receiving hemodialysis or peritoneal dialysis and reporting an eligible sleep-related outcome. One quasi-cluster randomized trial was retained as a documented protocol deviation. Standardized mean differences (SMDs) calculated using Hedges’ g and 95% confidence intervals (CIs) were pooled using random-effects models with restricted maximum-likelihood estimation and the Hartung–Knapp–Sidik–Jonkman adjustment (REML–HKSJ). Risk of bias was assessed using the revised Cochrane Risk of Bias tool for randomized trials (RoB 2), and evidence certainty was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. PROSPERO: CRD420251123449. Results: The 19 RCTs and one quasi-cluster randomized trial contributed an effective sample size of 1294 participants. The pooled estimate favored non-pharmacological interventions for sleep-related outcomes (Hedges’ g = −0.820, 95% CI −1.188 to −0.451; p = 0.0002), with substantial heterogeneity (I2 = 83.1%; τ2 = 0.4879). The 95% prediction interval (PI) ranged from −2.325 to 0.685. The pooled effects on anxiety symptoms (Hedges’ g = −0.29, 95% CI −0.99 to 0.41; p = 0.219), depressive symptoms (Hedges’ g = −0.64, 95% CI −2.32 to 1.04; p = 0.313), and fatigue symptoms (Hedges’ g = −0.41, 95% CI −0.93 to 0.11; p = 0.087) were not statistically significant. Effect estimates differed significantly by comparator type (Q-between = 11.28, df = 2; p = 0.0036). Conclusions: Non-pharmacological interventions may improve sleep-related outcomes in patients receiving dialysis for ESRD. However, substantial heterogeneity and a prediction interval crossing the null value limit confidence in the pooled estimate. Current evidence does not demonstrate clear benefits for anxiety symptoms, depressive symptoms, or fatigue symptoms.
- 9 September 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (18) , 2921
Open AccessNon-Pharmacological Interventions for Sleep Quality and Related Symptoms in Patients with End-Stage Renal Disease: A Systematic Review and Meta-Analysis
Background: Sleep-related problems are common among patients receiving dialysis for end-stage renal disease (ESRD), while pharmacological management may be complicated by comorbidities, polypharmacy, and altered drug clearance. This systematic review and meta-analysis evaluated the effects of non-pharmacological interventions on sleep-related outcomes, anxiety symptoms, depressive symptoms, and fatigue symptoms in this population. Methods: PubMed, Embase, the Cochrane Library, and Web of Science were searched from inception to February 2026. The prespecified eligibility criterion was restricted to randomized controlled trials (RCTs) involving adults with ESRD receiving hemodialysis or peritoneal dialysis and reporting an eligible sleep-related outcome. One quasi-cluster randomized trial was retained as a documented protocol deviation. Standardized mean differences (SMDs) calculated using Hedges’ g and 95% confidence intervals (CIs) were pooled using random-effects models with restricted maximum-likelihood estimation and the Hartung–Knapp–Sidik–Jonkman adjustment (REML–HKSJ). Risk of bias was assessed using the revised Cochrane Risk of Bias tool for randomized trials (RoB 2), and evidence certainty was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. PROSPERO: CRD420251123449. Results: The 19 RCTs and one quasi-cluster randomized trial contributed an effective sample size of 1294 participants. The pooled estimate favored non-pharmacological interventions for sleep-related outcomes (Hedges’ g = −0.820, 95% CI −1.188 to −0.451; p = 0.0002), with substantial heterogeneity (I2 = 83.1%; τ2 = 0.4879). The 95% prediction interval (PI) ranged from −2.325 to 0.685. The pooled effects on anxiety symptoms (Hedges’ g = −0.29, 95% CI −0.99 to 0.41; p = 0.219), depressive symptoms (Hedges’ g = −0.64, 95% CI −2.32 to 1.04; p = 0.313), and fatigue symptoms (Hedges’ g = −0.41, 95% CI −0.93 to 0.11; p = 0.087) were not statistically significant. Effect estimates differed significantly by comparator type (Q-between = 11.28, df = 2; p = 0.0036). Conclusions: Non-pharmacological interventions may improve sleep-related outcomes in patients receiving dialysis for ESRD. However, substantial heterogeneity and a prediction interval crossing the null value limit confidence in the pooled estimate. Current evidence does not demonstrate clear benefits for anxiety symptoms, depressive symptoms, or fatigue symptoms.
- Open Access
- 25 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (13) , 6089
Therapeutic Potential of CHCHD2 in Ischemia–Reperfusion Injury: Mechanistic Insights into Nrf2-Dependent Antioxidant Defense in HK2 Cells
Acute kidney injury (AKI) resulting from ischemia/reperfusion (I/R) poses a significant clinical challenge due to its high mortality and complex pathophysiology. Here, the protective actions of Coiled-coil-helix-coiled-coil-helix domain containing 2 (CHCHD2) in carbonyl cyanide m-chlorophenyl hydrazone (CCCP)-induced adenosine triphosphate depletion and recovery (ATP-D/R) injury in human kidney-2 (HK2) cells are examined. During ATP-D/R, expression levels of CHCHD2 were significantly reduced. The overexpression of CHCHD2 substantially reduced the levels of ROS, lipid peroxidation, apoptosis, kidney injury molecule-1 (KIM-1), and neutrophil gelatinase-associated lipocalin (NGAL), whereas the knockdown of CHCHD2 exacerbated cellular injury. Mechanistic studies further demonstrated that overexpression of CHCHD2 restored Nrf2 expression under ATP-D/R conditions, facilitated its nuclear translocation, and upregulated the downstream antioxidant enzyme HO-1. In contrast, the knockdown of Nrf2 reduced the cytoprotective actions of CHCHD2. These findings indicate that CHCHD2 reduces cellular damage by enhancing antioxidant defenses and reducing apoptosis through activating the Nrf2 axis, underscoring its potential as a therapeutic target for AKI.
- 25 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (13) , 6089
Open AccessTherapeutic Potential of CHCHD2 in Ischemia–Reperfusion Injury: Mechanistic Insights into Nrf2-Dependent Antioxidant Defense in HK2 Cells
Acute kidney injury (AKI) resulting from ischemia/reperfusion (I/R) poses a significant clinical challenge due to its high mortality and complex pathophysiology. Here, the protective actions of Coiled-coil-helix-coiled-coil-helix domain containing 2 (CHCHD2) in carbonyl cyanide m-chlorophenyl hydrazone (CCCP)-induced adenosine triphosphate depletion and recovery (ATP-D/R) injury in human kidney-2 (HK2) cells are examined. During ATP-D/R, expression levels of CHCHD2 were significantly reduced. The overexpression of CHCHD2 substantially reduced the levels of ROS, lipid peroxidation, apoptosis, kidney injury molecule-1 (KIM-1), and neutrophil gelatinase-associated lipocalin (NGAL), whereas the knockdown of CHCHD2 exacerbated cellular injury. Mechanistic studies further demonstrated that overexpression of CHCHD2 restored Nrf2 expression under ATP-D/R conditions, facilitated its nuclear translocation, and upregulated the downstream antioxidant enzyme HO-1. In contrast, the knockdown of Nrf2 reduced the cytoprotective actions of CHCHD2. These findings indicate that CHCHD2 reduces cellular damage by enhancing antioxidant defenses and reducing apoptosis through activating the Nrf2 axis, underscoring its potential as a therapeutic target for AKI.